Skip to main content
. 2022 Feb 16;6:e2100197. doi: 10.1200/PO.21.00197

FIG 2.

FIG 2.

(A) IDH-mutated ctDNA by ddPCR in serially collected plasma during therapy with IDH inhibitors. (B) Heatmap of mutations detected by digital NGS in ctDNA from patients with IDH-mutated cholangiocarcinoma treated with IDH inhibitors at baseline and progression. Red crosses mark samples that failed quality control. (C-G) Dynamic tracking of VAF for detected mutations in ctDNA (ddPCR) from serial plasma samples or tumor tissue (NGS sequencing) from serial biopsies in patients treated with IDH inhibitors. Bx, biopsy; ctDNA, circulating tumor DNA; ddPCR, droplet digital polymerase chain reaction; IDH, isocitrate dehydrogenase; IDHi-1, first IDH1 inhibitor; IDHi-2, second IDH inhibitor; mut, mutant without reported VAF; NGS, next-generation sequencing; PD, progressive disease; Pre-tx, pretreatment; SD, stable disease; VAF, variant allele frequency.